Key Highlights

  • Merck shares are up approximately 11.05 percent to $150.10, from Tuesday's close of $135.17, marking the stock's best Trading session since March 2009.
  • The surge follows this morning's announcement that Merck and Moderna's combination therapy met its primary and key secondary endpoints in a pivotal Phase 3 melanoma trial.
  • Shares have challenged their 52-week high during the session, supported by a strong second-quarter Earnings beat and a string of recent analyst price target increases.
  • Partner Moderna's stock jumped as much as 150 percent on the same news, marking its own best trading day ever.

Shares Post Best Trading Day in Over 16 Years

Merck shares are trading sharply higher, up about 11.05 percent to $150.10, marking the stock's best trading session since March 2009. The move follows this morning's announcement that intismeran autogene, an individualized mRNA-based cancer therapy jointly developed with Moderna, combined with Merck's KEYTRUDA, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in a pivotal Phase 3 melanoma trial.

Company Background and Strategic Significance

Merck & Co. (NYSE:MRK) is a leading global healthcare company headquartered in Rahway, New Jersey, with a pharmaceutical Business anchored by its KEYTRUDA immunotherapy Franchise across oncology, immunology, and infectious disease. Today's trial result marks the first-ever positive Phase 3 readout for an mRNA-based cancer therapy and reinforces Merck's efforts to diversify its oncology pipeline ahead of KEYTRUDA's looming Patent cliff, a strategic priority that has weighed on investor sentiment in recent years.

Rally Builds on Recent Earnings Strength

Today's advance builds on Merck's strong second-quarter earnings beat, which showed Revenue of $16.61 billion, and a string of recent analyst price target increases, pushing shares to challenge their 52-week high during the session. The news also sent partner Moderna's stock up as much as 150 percent, marking Moderna's best trading day ever, underscoring how significant a shift today's data represents for both companies' oncology ambitions.

What Comes Next

Merck shares are trading up about 11.05 percent to $150.10, marking the stock's best trading session since March 2009. These are the verified facts as reported. Whether today's gains hold may depend on how quickly the companies advance the therapy toward regulatory filings and how the market weighs this new oncology catalyst against KEYTRUDA's approaching patent expiration.